LSL Pharma Group Inc. (TSXV:LSL)

Paramount Global Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	17.75	10.03	8.21	8.77	10.05
Revenue Growth (YoY)	76.98%	22.08%	-6.35%	-12.70%	108.32%
Cost of Revenue	12.4	8.38	10.39	6.89	6.85
Gross Profit	5.35	1.65	-2.17	1.88	3.2
Selling, General & Admin	4.52	3.64	3.92	2.59	1.52
Research & Development	-	-	0.67	-	-
Operating Expenses	4.94	5.76	4.59	2.59	1.52
Operating Income	0.41	-4.12	-6.76	-0.71	1.68
Interest Expense	-1.9	-1.76	-1.39	-1.71	-1.26
Other Non Operating Income (Expenses)	-	-0.05	-0.15	-	-0.17
EBT Excluding Unusual Items	-1.5	-5.92	-8.29	-2.41	0.25
Merger & Restructuring Charges	-	-2.55	-0.43	-	-
Other Unusual Items	4.86	-	0.66	0.78	0.57
Pretax Income	3.37	-8.47	-8.06	-1.63	0.82
Income Tax Expense	0.05	-	-	0.15	0.21
Net Income	3.32	-8.47	-8.06	-1.78	0.61
Net Income to Common	3.32	-8.47	-8.06	-1.78	0.61
Net Income Growth	-	-	-	-	592.98%
Shares Outstanding (Basic)	105	80	66	59	55
Shares Outstanding (Diluted)	105	80	66	59	55
Shares Change (YoY)	31.18%	20.94%	11.78%	8.34%	14.88%
EPS (Basic)	0.03	-0.11	-0.12	-0.03	0.01
EPS (Diluted)	0.03	-0.11	-0.12	-0.03	0.01
EPS Growth	-	-	-	-	503.48%
Free Cash Flow	-3.25	-7.73	-4.16	-2	-4.47
Free Cash Flow Per Share	-0.03	-0.10	-0.06	-0.03	-0.08
Gross Margin	30.13%	16.40%	-26.44%	21.47%	31.83%
Operating Margin	2.29%	-41.05%	-82.26%	-8.07%	16.74%
Profit Margin	18.69%	-84.48%	-98.15%	-20.26%	6.07%
Free Cash Flow Margin	-18.31%	-77.04%	-50.66%	-22.80%	-44.47%
EBITDA	1.71	-3.21	-5.97	0.1	2.51
EBITDA Margin	9.61%	-32.03%	-72.67%	1.17%	25.01%
D&A For EBITDA	1.3	0.9	0.79	0.81	0.83
EBIT	0.41	-4.12	-6.76	-0.71	1.68
EBIT Margin	2.29%	-41.05%	-82.26%	-8.07%	16.74%
Effective Tax Rate	1.49%	-	-	-	25.92%
Revenue as Reported	17.75	10.03	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.